Skip to main content
Premium Trial:

Request an Annual Quote

NIDA to Fund Early-Stage Biochemists

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The National Institute on Drug Abuse has set aside $1.5 million to fund between six and eight proof-of-concept grants to young researchers who have not previously received National Institutes of Health funding and are studying chemistry that could be used in drug addiction research.

The grants are for up to $250,000 in direct costs over a two-year period and will be given to research chemists who seek to develop probes for use in basic research and to identify new or better templates as lead compounds for use in structure-activity relationship studies, including identification of potential new therapeutic chemicals.

Researchers who receive these early-stage grants may apply later for up to $250,000 per year over three years through a follow-up grant program.

NIDA wants researchers to study molecular, genetic, cellular, behavioral, and other mechanisms involved in drug abuse and addiction that may be of benefit in therapeutic approaches.

Studies that enhance knowledge of the chemistry of drug abuse can lead to new targets for interventions or new ways to treat toxic side-effects of drugs, and to new probes or technologies that has the potential to quickly advance the drug abuse research field, the institute said in an announcement of the grants.

Researchers can use the funds to develop biomarkers for diagnosis, prevention, and determination of the effectiveness of treatment using metabolomics, proteomics, and lipidomics technologies that are applied to research into drug abuse.

They also may aim to improve specific cell-based high-throughput assays for identifying new ligands for receptors, transporters, and enzymes.

Other research may use structural biology and biophysical studies, such as research into membrane-bound receptors and proteins, and biophysical methods that use nuclear magnetic resonance imaging, and cell or cellular materials to test and design novel ligands for target proteins, lipids, and other targets.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.